Macomics announces appointment of Simon Dew as new Chief Business Officer

Macomics Ltd, a leader in macrophage drug discovery has announced the appointment of Simon Dew in the newly created position of Chief Business Officer (CBO). He will be instrumental in advancing Macomics’ mission to develop first-in-class medicines targeting macrophage-driven diseases of high unmet medical need, in oncology and chronic inflammatory diseases.

With an extensive background in pharmaceutical business development, corporate strategy, Simon will play a pivotal role in maximizing the potential of Macomics’ proprietary macrophage ENIGMAC™ drug discovery platform through strategic partnerships and collaborations.

Simon brings over 25 years of experience in the pharmaceutical industry, having held senior leadership roles in Pharma and Biotech. He is currently on the Business Development Board of Sunstone Capital, a Danish Venture Capital Company and, most recently served as CBO at ReNeuron Group. His career also includes significant roles at Gyroscope Therapeutics, Astellas Pharmaceuticals, IQVIA, Parexel, Phytopharm plc, and GSK/SB, where he demonstrated exceptional expertise in business development, corporate strategy, and operational leadership. He has a BSc in Pharmacy and has completed the INSEAD Managing Partnerships and Strategic Alliances and M&A Executive Program.

Dr Stephen Myatt, CEO of Macomics said, “I am delighted to welcome Simon to the company. Business development is a critical role to our leadership team and Simon’s extensive experience and successful track record in the biotech and pharmaceutical industry will be invaluable as we continue to advance our macrophage-targeted therapies and expand our strategic partnerships. Macrophages are key to multiple diseases of high unmet medical need, including as key mediators of solid tumour immunosuppression and pathological inflammation in chronic inflammatory disorders.”

Simon Dew, new CBO of Macomics said, “The potential of the ENIGMAC platform to discover and develop novel macrophage-targeted therapies is unique, and I look forward to working with the talented team at Macomics to deliver on strategic partnerships that will accelerate the development of transformative medicines for patients with high unmet medical needs.”

Picture1.jpg 8

Simon Dew, Chief Business Officer, Macomics

More within